AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14636905
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg/day titrated to 80 mg/day
Trial: 14636905
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day titrated to 80 mg/day
Trial: 14636905
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 and 80 mg
Trial: 19064019
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (Rosuvastatin and Atorvastatin)
Trial: 8626819
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium intake (60.4 ± 6.5 mmol/day [2414 ± 260 mg/day]; n = 13)
Trial: 8626819
Drug: Usual calcium
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual calcium intake (20.4 ± 7.2 mmol/day [815 ± 289 mg/day]; n = 15)
Trial: 1589234
Drug: Intranasal salmon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal salmon calcitonin (3 x 100 U/day)
Trial: 1589234
Drug: Placebo (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (3 sprays)
Trial: 2424102
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus weekly injection of bleomycin 15 mg and mitomycin C 4 mg
Trial: 22765917
Drug: Aspirin (20mg/kg)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (20mg/kg) administered at 0h, 3h, or 24h after SE, followed by once daily treatment for 20 days
Trial: 22765917
Drug: Aspirin (20mg/kg)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (20mg/kg) administered after SE
Trial: 22765917
Drug: Aspirin (20mg/kg)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (20mg/kg) administered at 3h or 24h after SE
Trial: 15828938
Drug: LyphoDerm +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LyphoDerm + standard care (hydrocolloid dressing and compression therapy)
Trial: 15828938
Drug: LyphoDerm +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LyphoDerm + standard care (hydrocolloid dressing and compression therapy) in patients with enlarging ulcers
Trial: 12424538
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 12 (Group 1)
Trial: 12424538
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human G‐CSF (Lenograstim) 263 micro g/day SC starting from day 17 (Group 2)
Trial: 12424538
Drug: Historical control
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical control group (no G‐CSF)
Trial: 24796970
Drug: Lisdexamfetamine (LDX)
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine (LDX) 30, 50, or 70 mg/day
Trial: 19848574
Drug: Insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin aspart applied with the FlexPen (IAFP)
Trial: 19848574
Drug: Pulmonary human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pulmonary human insulin applied with the Exubera device (HIEX)
Trial: 27703286
Drug: Atracurium (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.5 mg/kg)
Trial: 22584638
Drug: Cisatracurium (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisatracurium (0.15 mg/kg)
Trial: 9576371
Drug: 1.1% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1% amino acid dialysis solution (Nutrineal)
Trial: 29972210
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (n=20) consuming a daily 200mL liquid juice containing 3000mg omega-3 PUFAs, 10μg vitamin D3, 150mg resveratrol, and 8g whey protein isolate
Trial: 29972210
Drug: Placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group (n=17) consuming a daily 200mL juice only
Trial: 23876590
Drug: Imidafenacin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imidafenacin (0.1 mg) twice daily
Trial: 19788433
Drug: Capsulin (150U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsulin (150U twice daily during repeat dosing)
Trial: 16487438
Drug: Euthyroid group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euthyroid group (L‐thyroxine plus placebo)
Trial: 16487438
Drug: Low‐TSH group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐TSH group (L‐thyroxine)
Trial: 1487561
Drug: Venlafaxine 25
RxNorm normalized name: venlafaxine 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine 25 mg
Trial: 3161013
Drug: Ketanserin (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (mean dose 71 mg/d)
Trial: 31326345
Drug: Faecal microbiota
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Faecal microbiota transplantation (FMT) capsules (75 capsules over 3 days, each containing approximately 0.38 g of minimally processed donor stool)
Trial: 31326345
Drug: Placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules (75 capsules over 3 days)
Trial: 29953740
Drug: High-fat diet
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat diet and liraglutide treatment (HFL)
Trial: 17888806
Drug: Problem-solving therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Problem-solving therapy plus usual care (PST-UC)
Trial: 8313397
Drug: Brofaromine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine (150 mg/day)
Trial: 4072939
Drug: Diltiazem (240
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (240 or 360 mg/day)
Trial: 18957
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg oral carbuterol
Trial: 18957
Drug: 35 mg
RxNorm normalized name: papain 35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 35 mg ephedrine sulfate
Trial: 25816713
Drug: atenolol (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (25-50 mg)
Trial: 25816713
Drug: bisoprolol (2.5-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bisoprolol (2.5-5 mg)
Trial: 8170529
Drug: both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both drugs
Trial: 23283255
Drug: Lidocaine 0.25
RxNorm normalized name: Bupivacaine Hydrochloride/Epinephrine/Lidocaine 0.25%-1 MG/1 ML-1% Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.25 mg/kg
Trial: 23283255
Drug: Lidocaine 0.5
RxNorm normalized name: LIDOCAINE 0.5% GEL,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 0.5 mg/kg
Trial: 20723985
Drug: PAPP-A levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAPP-A levels ≥ 11.33 mIu/L
Trial: 20723985
Drug: PAPP-A levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAPP-A levels < 11.33 mIu/L
Trial: 20077989
Drug: Performance Intervention
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Performance Intervention (fostering daily mobility and activity)
Trial: 17259484
Drug: Vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (100 mg daily, divided doses)
Trial: 17259484
Drug: Rosiglitazone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (8 mg daily, once daily)
Trial: 15634825
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of methadone
Trial: 15634825
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of morphine
Trial: 15634825
Drug: 0.5 mL
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL of saline solution
Trial: 12059047
Drug: AIT-082 (0.6,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AIT-082 (0.6, 2.0, 6.0, and 20.0 mg/kg)
Trial: 7733089
Drug: Nipradilol 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nipradilol 6 mg twice a day (n = 14)
Trial: 2209498
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (Cefotaxime 2 g i.v. 15 min before the procedure)
Trial: 7421359
Drug: Quinine sulphate
RxNorm normalized name: Quinine sulphate
DrugBank: Quinine (DB00468)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quinine sulphate (300 mg capsule)
Trial: 24063212
Drug: Tongjiang Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongjiang Granule (TJG), 10 g each time, three times a day for 4 weeks
Trial: 24063212
Drug: Omeprazole Tablet,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole Tablet, 20 mg each time, two times a day for 4 weeks
Trial: 17950797
Drug: Coenzyme Q(10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q(10) (200 mg/day)
Trial: 21370966
Drug: Coenzyme Q(10)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coenzyme Q(10) (200 mg/day) vs Placebo
Trial: 17722619
Drug: Rectal suppositories
RxNorm normalized name: Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal suppositories vitaprost forte
Trial: 15104911
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy (CBT) delivered by videoconference
Trial: 15104911
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy (CBT) delivered face-to-face
Trial: 11361049
Drug: GW420867X 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 100 mg (fasted state)
Trial: 11361049
Drug: GW420867X 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 100 mg (high-fat meal)
Trial: 11361049
Drug: GW420867X 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW420867X 100 mg (normal fat meal)
Trial: 7986784
Drug: Concentrated soya-bean-protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated soya-bean-protein solution (isolate)
Trial: 28805759
Drug: Long-acting pentoxifylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting pentoxifylline (vasonite) in combined therapy
Trial: 26125259
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX-A) treatment
Trial: 26125259
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX-A) treatment combined with orthopedic joint brace
Trial: 31562145
Drug: Oral medications
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medications
Trial: 23042612
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) - seven individual sessions concurrent with radiotherapy
Trial: 23042612
Drug: Non-directive supportive
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-directive supportive counseling (SC) - seven individual sessions concurrent with radiotherapy
Trial: 16462661
Drug: Cefpodoxime-proxetil (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpodoxime-proxetil (200 mg bid for 5 days)
Trial: 16462661
Drug: Amoxicillin-clavulanic acid
RxNorm normalized name: amoxicillin / clavulanate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin-clavulanic acid (1 g/125 mg bid for 8 days)
Trial: 11760163
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g t.i.d.) + Amikacin (15 mg/kg/o.d.)
Trial: 11760163
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g b.i.d.) + Amikacin (15 mg/kg/o.d.)
Trial: 6412584
Drug: Droperidol 5
RxNorm normalized name: droPERidol 5 MG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 5 mg
Trial: 6412584
Drug: Etomidate 10
RxNorm normalized name: metomidate 1000 mg in 1 g TOPICAL POWDER [Aquacalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 10 mg
Trial: 24980836
Drug: 8-week yoga
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8-week yoga intervention (n=15), consisting of a weekly 90-minute teacher-led class and a 40-minute daily session delivered by DVD
Trial: 14716420
Drug: Hapavax-Gene vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hapavax-Gene vaccine (10 microgram doses for ages 10-19, 20 microgram doses for ages over 19) administered intramuscularly in three doses: day 0, after 30 days, and after 180 days.
Trial: 7917735
Drug: suxamethonium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suxamethonium 1.5 mg kg‐1
Trial: 20112574
Drug: Infrared therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infrared therapy
Trial: 15306594
Drug: PhiCal test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PhiCal test (calprotectin level > or =50 microg/g)
Trial: 8292066
Drug: Compressed naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compressed naproxen suppositories (250 mg)
Trial: 8292066
Drug: Standard naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard naproxen tablet
Trial: 30955977
Drug: Chemotherapy (investigator's
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (investigator's choice of platinum-based chemotherapy for four to six cycles)
Trial: 26924360
Drug: O-(beta-Hydroxyethyl)-rutosides (Oxerutin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: O-(beta-Hydroxyethyl)-rutosides (Oxerutin), 500 mg po q12hr
Trial: 22035463
Drug: Aliskiren 150
RxNorm normalized name: aliskiren 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 150 mg once daily
Trial: 19145003
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily
Trial: 22035463
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily + HCTZ 12.5 mg once daily
Trial: 22035463
Drug: Aliskiren 300
RxNorm normalized name: aliskiren 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren 300 mg once daily + HCTZ 25 mg once daily
Trial: 14651394
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination or PSA test
Trial: 11089748
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine gel, three times a day during the ICU stay
Trial: 17279004
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral care
Trial: 10334346
Drug: Prednisolone acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone acetate 1.0% ophthalmic suspension
Trial: 8452179
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg) given as a single dose
Trial: 8452179
Drug: Fleroxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin (400 mg) given once daily for 3 days
Trial: 3940260
Drug: Loperamide (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (12 mg)
Trial: 27082519
Drug: Nasal oxygen
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal oxygen insufflation (100 mL/kg/min, estimated 37% FiO2, n = 9)
Trial: 20691328
Drug: New cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New cognitive behavioural treatment
Trial: 20691328
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy (leading alternative psychological treatment)
Trial: 9475020
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no adjunctive antimetabolites)
Trial: 7947383
Drug: Nisoldipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (20 mg once daily)
Trial: 2828249
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with theophylline
Trial: 2828249
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with terbutaline
Trial: 30509185
Drug: Specific micronutrient
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific micronutrient combination
Trial: 21937705
Drug: Vinorelbine/Gemcitabine doublet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine/Gemcitabine doublet (VG arm: vinorelbine 25 mg/m2; gemcitabine 1000 mg/m2 on days 1 and 15)
Trial: 21937705
Drug: Capecitabine (Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine (Cap arm: 1250 mg/m2 twice daily, on days 1-14)
Trial: 29538089
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment response
Trial: 17184890
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 mg)
Trial: 17184890
Drug: Methamphetamine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (15 mg)
Trial: 17184890
Drug: Methamphetamine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methamphetamine (30 mg)
Trial: 16084254
Drug: Combination antibiotic
RxNorm normalized name: combinations of different antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antibiotic susceptibility testing (MCBT)
Trial: 12898820
Drug: Acute stage
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acute stage of disease (before treatment)
Trial: 12898820
Drug: After clearing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After clearing of skin lesions (after effective treatment)
Trial: 7770260
Drug: 2 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g/day of elemental calcium
Trial: 7486112
Drug: Nitroprusside treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside treatment
Trial: 31116188
Drug: 6-mm-long and
RxNorm normalized name: LONG PEPPER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-mm-long and 4-mm-wide implants
Trial: 31116188
Drug: Implants at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implants at least 10-mm long in augmented bone
Trial: 28318845
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of positive affect‐oriented communication and positive expectation
Trial: 24167605
Drug: Advice to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advice to take iron supplements
Trial: 24167605
Drug: Length of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Length of time that iron supplements had been taken
Trial: 17763203
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg bd)
Trial: 17763203
Drug: Rofecoxib (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (12.5 mg bd)
Trial: 2396471
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x S (three doses of suspension-formulated vaccine)
Trial: 2396471
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x E (three doses of vaccine in enteric-coated capsules)
Trial: 2396471
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x S (two doses of suspension-formulated vaccine)
Trial: 2396471
Drug: 1 x
RxNorm normalized name: Black Cohosh 1 X Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 x S (one dose of suspension-formulated vaccine)
Trial: 30138543
Drug: Glucocorticoid (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid (20 mg prednisolone)
Trial: 30138543
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mg Avicel)
Trial: 22463922
Drug: SAR236553 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR236553 50 mg Q2W
Trial: 22463922
Drug: SAR236553 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR236553 100 mg Q2W
Trial: 22463922
Drug: SAR236553 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR236553 150 mg Q2W
Trial: 22463922
Drug: SAR236553 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR236553 200 mg Q4W
Trial: 22463922
Drug: SAR236553 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAR236553 300 mg Q4W
Trial: 20934557
Drug: 200-mg intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200-mg intravenous bolus of potassium canrenoate followed by a daily 25-mg dose of spironolactone for 6 months